Neuphoria Therapeutics Inc. (NEUP) — DEFA14A Filings
All DEFA14A filings from Neuphoria Therapeutics Inc.. Browse 7 DEFA14A reports with AI-powered summaries and risk analysis.
DEFA14A Filings (7)
- DEFA14A Filing — Dec 8, 2025
-
Neuphoria Responds to Lynx1's Revised Offer
— Dec 4, 2025 Risk: medium
Neuphoria Therapeutics Inc. filed definitive additional materials on December 4, 2025, in response to Lynx1's revised indication of interest. Lynx1 has proposed -
Neuphoria Fires Back at Lynx1, Exposes 'False Narratives'
— Dec 1, 2025 Risk: medium
Neuphoria Therapeutics Inc. filed a Definitive Additional Materials document (DEFA14A) on December 1, 2025, responding to claims made by Lynx1. The company stat -
Neuphoria Therapeutics Files Definitive Additional Materials
— Nov 25, 2025 Risk: low
Neuphoria Therapeutics Inc. filed definitive additional materials (DEFA14A) on November 25, 2025. This filing relates to proxy statements under Section 14(a) of -
Neuphoria Therapeutics Files Definitive Proxy Materials
— Nov 24, 2025 Risk: low
Neuphoria Therapeutics Inc. filed definitive additional materials on November 24, 2025, related to its proxy statement. The company, formerly known as Bionomics -
Neuphoria Therapeutics Initiates Strategic Review
— Nov 12, 2025 Risk: medium
Neuphoria Therapeutics Inc. (NEO) announced on November 12, 2025, the initiation of a strategic review process to explore all options for maximizing stockholder -
Bionomics Files Definitive Additional Materials
— Nov 13, 2024 Risk: low
Bionomics Limited filed definitive additional materials on November 13, 2024, related to its proxy statement. The filing indicates no fee was required for this
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX